certolizumab pegol vs etanercept

NCT03357471 · Phase 3 · completed

Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.

NCT03780959 · Phase 2/3 · completed

After 90 days of open-label etanercept, 51 responding children were randomized to continue etanercept or receive placebo in a double-blind comparison. The clinical primary endpoint, disease flare, was met in favor of etanercept (28% vs 81% with placebo; p=0.0030), but the randomized sample was small, limiting the strength of the evidence.

NCT02326272 · Phase 3 · completed

This was a randomized, double-blind (quadruple-masked), placebo-controlled trial in 227 adults with moderate-to-severe plaque psoriasis. Both the 200 mg and 400 mg certolizumab pegol doses produced significantly higher rates of skin clearance (PASI75: 81.4% and 82.6% vs 11.6% placebo) and physician-assessed clearance (66.8% and 71.6% vs 2.0% placebo) at week 16, both p<0.0001.

NCT00317499 · Phase 3 · completed

Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.

NCT03357471 · Phase 3 · completed

Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.

NCT00317499 · Phase 3 · completed

Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.